Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study

Clinical Immunology

Volumn 154, Issue 2, 2014, Pages 141-154

  Millan O ^a,b   Rafael Valdivia, L ^c   San Segundo, D ^d   Boix, F ^e   Castro Panete, M J ^f   Lopez Hoyos M ^d   Muro, M ^e   Valero Hervas D ^f   Rimola, A ^b,c   Navasa, M ^b,c   Munoz P ^g   Miras, M ^e   Andres A ^f   Guirado, L ^h   Pascual, J ⁱ   Brunet, M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g Servicio Cantabro de Salud   (Spain)

^h FUNDACIÓ PUIGVERT   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

Author keywords

Acute rejection; ; Bootstrap; IFN , IL 2 and IL 17; ; Kidney transplantation; ; Liver transplantation;

Indexed keywords

AMINOTRANSFERASE; BASILIXIMAB; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CAUCASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT DISEASE;

ACUTE REJECTION;; BOOTSTRAP; IFN-Γ, IL-2 AND IL-17;; KIDNEY TRANSPLANTATION;; LIVER TRANSPLANTATION;;

ADULT; BIOLOGICAL MARKERS; FEMALE; GRAFT REJECTION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE;

EID: 84905867612     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.07.007     Document Type: Article

References (45)

1. Roedder S., Vitalone M., Khatri P., Sarwal M.M. Biomarkers in solid organ transplantation: establishing personalized transplantation medicine. Genome Med. 2011, 3(6):37.
2. Hernandez-Fuentes M.P., Lechler R.I. A 'biomarker signature' for tolerance in transplantation. Nat. Rev. Nephrol. 2010, 6(10):606-613.
3. Heidt S., San Segundo D., Shankar S., Mittal S., Muthusamy A.S., Friend P.J., et al. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011, 92(1):1-9.
4. + T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection. Transpl. Immunol. 2005, 14(1):21-25.
5. Fan H., Li L.X., Han D.D., Kou J.T., Li P., He Q. Increase of peripheral Th17 lymphocytes during acute cellular rejection in liver transplant recipients. Hepatobiliary Pancreat. Dis. Int. 2012, 11(6):606-611.
6. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25:821-852.
7. Homey B. After TH1/TH2 now comes Treg/TH17: significance of T helper cells in immune response organization. Hautarzt 2006, 57(8):730-732.
8. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J. Biol. Chem. 2008, 283(25):17003-17008.
9. Le Moine A., Goldman M., Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002, 73(9):1373-1381.
10. Karczewski J., Karczewski M., Wiktorowicz K. Pretransplant urine cytokine pattern predicts acute kidney rejection. Cytokine 2010, 51(1):10-11.
11. Atalar K., Afzali B., Lord G., Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr. Opin. Organ Transplant. 2009, 14(1):23-29.
12. Boleslawski E., Conti F., Sanquer S., Podevin P., Chouzenoux S., Batteux F., et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004, 77(12):1815-1820.
13. Millan O., Benitez C., Guillen D., Lopez A., Rimola A., Sanchez-Fueyo A., et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin. Immunol. 2010, 137(3):337-346.
14. Millan O., Rafael-Valdivia L., Torrademe E., Lopez A., Fortuna V., Sanchez-Cabus S., et al. Intracellular IFN-gamma and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine 2013, 61(2):556-564.
15. Nickel P., Presber F., Bold G., Biti D., Schonemann C., Tullius S.G., et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12months in renal-transplant recipients. Transplantation 2004, 78(11):1640-1646.
16. Kim S.H., Oh E.J., Kim M.J., Park Y.J., Han K., Yang H.J., et al. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant. Proc. 2007, 39(10):3057-3060.
17. Bestard O., Nickel P., Cruzado J.M., Schoenemann C., Boenisch O., Sefrin A., et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J. Am. Soc. Nephrol. 2008, 19(7):1419-1429.
18. Antonysamy M.A., Fanslow W.C., Fu F., Li W., Qian S., Troutt A.B., et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J. Immunol. 1999, 162(1):577-584.
19. Tang J.L., Subbotin V.M., Antonysamy M.A., Troutt A.B., Rao A.S., Thomson A.W. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001, 72(2):348-350.
20. Hsieh H.G., Loong C.C., Lui W.Y., Chen A., Lin C.Y. IL-17 expression as a possible predictive parameter for subclinical renal allograft rejection. Transpl. Int. 2001, 14(5):287-298.
21. Fabrega E., Lopez-Hoyos M., San Segundo D., Casafont F., Pons-Romero F. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl. 2009, 15(6):629-633.
22. Loverre A., Tataranni T., Castellano G., Divella C., Battaglia M., Ditonno P., et al. IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibody-mediated rejection. Am. J. Transplant. 2011, 11(6):1248-1259.
23. Clavien P. Medical Care of the Liver Transplant Patient 2012, John Wiley & Sons, Ltd, Oxford. 4th ed.
24. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997, 25(3):658-663.
25. Brunet M., Cirera I., Martorell J., Vidal E., Millan O., Jimenez O., et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006, 81(4):541-546.
26. Grinyo J.M., Ekberg H., Mamelok R.D., Oppenheimer F., Sanchez-Plumed J., Gentil M.A., et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol. Dial. Transplant. 2009, 24(7):2269-2276.
27. Pala P., Hussell T., Openshaw P.J. Flow cytometric measurement of intracellular cytokines. J. Immunol. Methods 2000, 243(1-2):107-124.
28. Godoy-Ramirez K., Franck K., Mahdavifar S., Andersson L., Gaines H. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J. Immunol. Methods 2004, 292(1-2):1-15.
29. Youden W. Index for ratting diagnosis test. Cancer Biol. Ther. 1950, 3:32-35.
30. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143(1):29-36.
31. Hosmer D., Lemeshow S. Model-building strategies and methods for logistic regression. Applied Logistic Regression 2000, 91-142. Wiley, New York. 2nd ed. D. Hosmer, S. Lemeshow (Eds.).
32. Mickey R.M., Greenland S. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 1989, 129(1):125-137.
33. Hilbe J. Model development. Logistic Regression Models 2009, 73-187. Chapman & Hall/CRC Press, Boca Raton. J. Hilbe (Ed.).
34. Harrell F.E. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis 2001, Springer-Verlag, New York.
35. Harrel F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15:361-387.
36. Schirren C.A., Jung M., Worzfeld T., Mamin M., Baretton G.B., Gruener N.H., et al. Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection. Liver Transpl. 2000, 6(2):222-228.
37. Akoglu B., Kriener S., Martens S., Herrmann E., Hofmann W.P., Milovic V., et al. Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients. Clin. Exp. Med. 2009, 9(4):259-262.
38. Okanami Y., Tsujimura K., Mizuno S., Tabata M., Isaji S., Akatsuka Y., et al. Intracellular interferon-gamma staining analysis of donor-specific T-cell responses in liver transplant recipients. Transplant. Proc. 2012, 44(2):548-554.
39. Kim Y., Park K.H., Chung B.H., Choi B.S., Yang C.W., Kim J.I., et al. Pretransplant IFN-gamma ELISPOT assay as a potential screening test to select immunosuppression protocols for patients receiving basiliximab induction therapy. Transl. Res. 2012, 160(3):230-236.
40. de Menezes Neves P.D., Machado J.R., dos Reis M.A., Faleiros A.C., de Lima Pereira S.A., Rodrigues D.B. Distinct expression of interleukin 17, tumor necrosis factor alpha, transforming growth factor beta, and forkhead box P3 in acute rejection after kidney transplantation. Ann. Diagn. Pathol. 2013, 17(1):75-79.
41. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6(11):1123-1132.
42. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6(11):1133-1141.
43. Chen Y., Wood K.J. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection?. Transplantation 2007, 84(9):1071-1074.
44. Vergani A., Tezza S., D'Addio F., Fotino C., Liu K., Niewczas M., et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 2013, 127:463-475.
45. Steyerberg E.W., Harrell F.E., Borsboom G.J., et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J. Clin. Epidemiol. 2001, 54:774-781.